Articles

Resource use and outcomes associated with initiation of injectable therapies for patients with type 2 diabetes mellitus

Richard Brice, Sharon Shelley, Pankaj Chaturvedi, Divina Glah, Donna Ashley, Monica Hadi

Article Type

Original Research

Published

Management of type 2 diabetes mellitus (T2DM) often requires intervention with oral and injectable therapies. Across National Health Service (NHS) England, injectable therapies may be initiated in secondary, intermediate or primary care. This original research set out to understand resource utilization, the pathways of care, clinical outcomes, and experience of patients with T2DM
initiated on injectable therapies.

Read more

Willingness of European healthcare workers to undergo vaccination against seasonal influenza: current situation and suggestions for improvement

George Kassianos

Article Type

Case Report

Published

Uptake of vaccination against seasonal influenza in healthcare
workers (HCWs) is, in general, low (vaccine coverage of 6–54%), as is awareness of its importance, and has been decreasing in most European Union (EU) countries in recent years. This article clarifies the current situation and makes suggestions for improvement.

Read more

Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of anti-diabetic agents

Eva M Vivian

Article Type

Review

Published

Although several treatment options are available to reduce hyperglycemia, only about half of individuals with diagnosed diabetes mellitus (DM) achieve recommended glycemic targets. New agents that reduce blood glucose concentrations by novel mechanisms and have acceptable safety profiles are needed to improve glycemic control and reduce complications. This article reviews the evidence from clinical trials and suggests that SGLT2 inhibitors are a promising new treatment option for T2DM.

Read more

The cost of biologics for psoriasis is increasing

Judy Cheng, Steven R Feldman

Article Type

Original Research

Published

Biologic agents have revolutionized the management of psoriasis but at a higher cost compared with “traditional” agents. Cost must be considered when evaluating management options for psoriasis. This piece of original research To estimates the annual cost of treatment of psoriasis using biologic agents and assess the trend over the past decade.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.